TD Asset Management’s Zimmer Biomet ZBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.26M Sell
72,708
-14,992
-17% -$1.31M 0.01% 768
2026
Q1
$7.93M Buy
87,700
+1,293
+1% +$119K 0.01% 700
2025
Q4
$7.77M Buy
86,407
+4,241
+5% +$402K 0.01% 719
2025
Q3
$8.09M Buy
82,166
+8,147
+11% +$807K 0.01% 703
2025
Q2
$6.75M Sell
74,019
-4,177
-5% -$404K 0.01% 726
2025
Q1
$8.85M Sell
78,196
-333
-0.4% -$35.6K 0.01% 663
2024
Q4
$8.3M Buy
78,529
+1,033
+1% +$111K 0.01% 686
2024
Q3
$8.39M Buy
77,496
+96
+0.1% +$10.5K 0.01% 678
2024
Q2
$8.4M Sell
77,400
-99,839
-56% -$11.8M 0.01% 653
2024
Q1
$23.4M Buy
177,239
+7,644
+5% +$955K 0.02% 450
2023
Q4
$20.6M Buy
169,595
+15,552
+10% +$1.74M 0.02% 470
2023
Q3
$17.3M Sell
154,043
-4,102
-3% -$521K 0.02% 460
2023
Q2
$23M Buy
158,145
+33,091
+26% +$4.5M 0.03% 416
2023
Q1
$16.2M Buy
125,054
+14,284
+13% +$1.79M 0.02% 485
2022
Q4
$14.1M Buy
110,770
+5,632
+5% +$654K 0.02% 517
2022
Q3
$11.3M Sell
105,138
-6,510
-6% -$714K 0.01% 551
2022
Q2
$11.7M Sell
111,648
-2,348
-2% -$279K 0.01% 560
2022
Q1
$14.6M Sell
113,996
-3,337
-3% -$402K 0.01% 554
2021
Q4
$14.5M Buy
117,333
+271
+0.2% +$35.5K 0.01% 590
2021
Q3
$16.6M Buy
117,062
+5,946
+5% +$875K 0.02% 519
2021
Q2
$17.6M Buy
111,116
+8,268
+8% +$1.34M 0.02% 509
2021
Q1
$16M Buy
102,848
+4,006
+4% +$621K 0.02% 522
2020
Q4
$14.8M Buy
98,842
+7,612
+8% +$1.08M 0.02% 493
2020
Q3
$12.1M Buy
91,230
+21,464
+31% +$2.8M 0.02% 497
2020
Q2
$8.09M Sell
69,766
-5,775
-8% -$665K 0.01% 556
2020
Q1
$7.41M Buy
75,541
+4,810
+7% +$631K 0.01% 547
2019
Q4
$10.3M Sell
70,731
-8,269
-10% -$1.14M 0.01% 541
2019
Q3
$10.5M Sell
79,000
-3,677
-4% -$475K 0.02% 504
2019
Q2
$9.45M Buy
82,677
+3,771
+5% +$442K 0.01% 538
2019
Q1
$9.78M Buy
78,906
+4,274
+6% +$486K 0.01% 527
2018
Q4
$7.51M Buy
74,632
+15,145
+25% +$1.7M 0.01% 551
2018
Q3
$7.59M Sell
59,487
-4,228
-7% -$503K 0.01% 612
2018
Q2
$6.89M Buy
63,715
+438
+0.7% +$47.7K 0.01% 610
2018
Q1
$6.7M Sell
63,277
-2,489
-4% -$289K 0.01% 600
2017
Q4
$7.71M Sell
65,766
-2,720
-4% -$308K 0.01% 583
2017
Q3
$7.79M Sell
68,486
-3,991
-6% -$461K 0.01% 565
2017
Q2
$9.04M Sell
72,477
-5,265
-7% -$624K 0.01% 547
2017
Q1
$9.22M Sell
77,742
-454
-0.6% -$51.5K 0.01% 551
2016
Q4
$7.83M Sell
78,196
-17,271
-18% -$1.85M 0.01% 575
2016
Q3
$12.1M Buy
95,467
+4,532
+5% +$560K 0.02% 477
2016
Q2
$10.6M Buy
90,935
+8,652
+11% +$979K 0.02% 497
2016
Q1
$8.52M Sell
82,283
-705
-0.8% -$68.2K 0.02% 534
2015
Q4
$8.27M Buy
82,988
+2,163
+3% +$212K 0.02% 525
2015
Q3
$7.37M Sell
80,825
-824
-1% -$82.6K 0.01% 534
2015
Q2
$8.66M Buy
81,649
+4,059
+5% +$449K 0.02% 544
2015
Q1
$8.85M Buy
77,590
+1,165
+2% +$133K 0.02% 524
2014
Q4
$8.42M Buy
76,425
+2,549
+3% +$269K 0.01% 533
2014
Q3
$7.21M Sell
73,876
-41,147
-36% -$4.05M 0.01% 551
2014
Q2
$11.6M Sell
115,023
-5,681
-5% -$554K 0.02% 442
2014
Q1
$11.1M Sell
120,704
-988
-0.8% -$91.1K 0.02% 443
2013
Q4
$11M Sell
121,692
-7,082
-5% -$613K 0.02% 426
2013
Q3
$10.3M Buy
128,774
+14,046
+12% +$1.11M 0.02% 423
2013
Q2
$8.35M Buy
+114,728
New +$8.58M 0.02% 449

Other funds holding ZBH

TD Asset Management's ZBH Position: Q2 2026 in Review

TD Asset Management reduced its Zimmer Biomet (ZBH) stake by 17% in Q2 2026, selling an estimated $1.31M and leaving 72,708 shares worth $6.26M. The position accounts for 0.01% of the portfolio, ranked #768.

TD Asset Management first reported a position in ZBH in Q2 2013 and has held it in 53 quarters since. The position peaked at $23.4M in Q1 2024. 744 funds tracked by Wall St. Rank hold ZBH as of Q2 2026.

  • TD Asset Management held 72,708 shares of Zimmer Biomet worth $6.26M as of Q2 2026.
  • TD Asset Management sold 14,992 Zimmer Biomet shares in Q2 2026, an estimated $1.31M.
  • Zimmer Biomet made up 0.01% of TD Asset Management's portfolio in Q2 2026, its #768 holding.
  • TD Asset Management first reported a position in Zimmer Biomet in Q2 2013 and has held it in 53 quarters since.
  • TD Asset Management's Zimmer Biomet position peaked at $23.4M in Q1 2024.
  • 744 funds tracked by Wall St. Rank held Zimmer Biomet as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.